Home » Business » Manufacturing
Pfizer's vaccine sale
By Cathy Ding |
June 1, 2010, Tuesday
|
Print Edition
Print Edition
PFIZER Inc is said to have sold its swine vaccine business in China to Harbin Pharmaceutical Group.
Harbin Pharmaceutical has paid US$50 million for these assets, Reuters said, citing an unnamed source close to the deal.
A communications official from Pfizer yesterday said the company "did sell some of the animal health operations in China recently," but didn't give further details.
Pfizer will sell its China operations to manufacture its RespiSure and RespiSure-One swine mycoplasma hyopneumoniae (MH) vaccines to Harbin Bio-Vaccine, an animal health unit of Harbin Pharmaceutical.
The divestment is said to be connected to Pfizer's US$68 billion merger with Wyeth, as China's Ministry of Commerce ordered Pfizer to sell its local business citing anti-monopoly regulations, Reuters said.
Harbin Pharmaceutical has paid US$50 million for these assets, Reuters said, citing an unnamed source close to the deal.
A communications official from Pfizer yesterday said the company "did sell some of the animal health operations in China recently," but didn't give further details.
Pfizer will sell its China operations to manufacture its RespiSure and RespiSure-One swine mycoplasma hyopneumoniae (MH) vaccines to Harbin Bio-Vaccine, an animal health unit of Harbin Pharmaceutical.
The divestment is said to be connected to Pfizer's US$68 billion merger with Wyeth, as China's Ministry of Commerce ordered Pfizer to sell its local business citing anti-monopoly regulations, Reuters said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
